中国中西医结合肾病杂志
中國中西醫結閤腎病雜誌
중국중서의결합신병잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN NEPHROLOGY
2014年
10期
877-879
,共3页
钱春梅%王秦%许涛%盛晓华%汪年松
錢春梅%王秦%許濤%盛曉華%汪年鬆
전춘매%왕진%허도%성효화%왕년송
重组人红细胞生成素%蔗糖铁%左卡尼汀%维持性血液透析%C 反应蛋白
重組人紅細胞生成素%蔗糖鐵%左卡尼汀%維持性血液透析%C 反應蛋白
중조인홍세포생성소%자당철%좌잡니정%유지성혈액투석%C 반응단백
Human erythropoietin%Iron sucrose%L - Carnitine%Maintenance hemodialysis%C reactive protein
目的:观察重组人红细胞生成素联合蔗糖铁、左卡尼汀治疗维持性血液透析(MHD)患者的临床疗效,研究左卡尼汀对糖尿病肾病 MHD 患者炎症改善情况。方法:166例维持性血液透析患者随机分为 A、B、C 三组,其中 A 组单纯应用益比奥,B 组益比奥联合应用蔗糖铁,C 组益比奥联合应用蔗糖铁及左卡尼汀,疗程为1年,观察治疗前后3组患者血红蛋白(Hb)、血细胞比容(HCT)、C 反应蛋白(CRP)和主要生化指标(三酰甘油、胆固醇、总蛋白、白蛋白等)的变化。同时将 C 组维持性血液透析患者根据原发疾病分为糖尿病组(18例)与非糖尿病组(40例),观察两组白细胞、中性粒细胞和 CRP 的组间差异。结果:3组患者血红蛋白均有所上升,但 C 组患者血红蛋白较 A、B 组有显著性明显改善(P <0.05);3组患者治疗前CRP 水平无明显差异,治疗后均有显著性下降(P <0.05),同时治疗后 C 组较 A 组差异有统计学意义(P <0.05)。C 组患者中糖尿病肾病组与非糖尿病肾病组 CRP 水平均显著性下降(P <0.05),但糖尿病肾病较非糖尿病肾病组下降更显著。结论:左卡尼汀联合 EPO 和蔗糖铁治疗肾性贫血疗效优于简单给予 EPO 和蔗糖铁治疗,并能有效控制糖尿病肾病 MHD 患者微炎症状态,改善患者生存质量。
目的:觀察重組人紅細胞生成素聯閤蔗糖鐵、左卡尼汀治療維持性血液透析(MHD)患者的臨床療效,研究左卡尼汀對糖尿病腎病 MHD 患者炎癥改善情況。方法:166例維持性血液透析患者隨機分為 A、B、C 三組,其中 A 組單純應用益比奧,B 組益比奧聯閤應用蔗糖鐵,C 組益比奧聯閤應用蔗糖鐵及左卡尼汀,療程為1年,觀察治療前後3組患者血紅蛋白(Hb)、血細胞比容(HCT)、C 反應蛋白(CRP)和主要生化指標(三酰甘油、膽固醇、總蛋白、白蛋白等)的變化。同時將 C 組維持性血液透析患者根據原髮疾病分為糖尿病組(18例)與非糖尿病組(40例),觀察兩組白細胞、中性粒細胞和 CRP 的組間差異。結果:3組患者血紅蛋白均有所上升,但 C 組患者血紅蛋白較 A、B 組有顯著性明顯改善(P <0.05);3組患者治療前CRP 水平無明顯差異,治療後均有顯著性下降(P <0.05),同時治療後 C 組較 A 組差異有統計學意義(P <0.05)。C 組患者中糖尿病腎病組與非糖尿病腎病組 CRP 水平均顯著性下降(P <0.05),但糖尿病腎病較非糖尿病腎病組下降更顯著。結論:左卡尼汀聯閤 EPO 和蔗糖鐵治療腎性貧血療效優于簡單給予 EPO 和蔗糖鐵治療,併能有效控製糖尿病腎病 MHD 患者微炎癥狀態,改善患者生存質量。
목적:관찰중조인홍세포생성소연합자당철、좌잡니정치료유지성혈액투석(MHD)환자적림상료효,연구좌잡니정대당뇨병신병 MHD 환자염증개선정황。방법:166례유지성혈액투석환자수궤분위 A、B、C 삼조,기중 A 조단순응용익비오,B 조익비오연합응용자당철,C 조익비오연합응용자당철급좌잡니정,료정위1년,관찰치료전후3조환자혈홍단백(Hb)、혈세포비용(HCT)、C 반응단백(CRP)화주요생화지표(삼선감유、담고순、총단백、백단백등)적변화。동시장 C 조유지성혈액투석환자근거원발질병분위당뇨병조(18례)여비당뇨병조(40례),관찰량조백세포、중성립세포화 CRP 적조간차이。결과:3조환자혈홍단백균유소상승,단 C 조환자혈홍단백교 A、B 조유현저성명현개선(P <0.05);3조환자치료전CRP 수평무명현차이,치료후균유현저성하강(P <0.05),동시치료후 C 조교 A 조차이유통계학의의(P <0.05)。C 조환자중당뇨병신병조여비당뇨병신병조 CRP 수평균현저성하강(P <0.05),단당뇨병신병교비당뇨병신병조하강경현저。결론:좌잡니정연합 EPO 화자당철치료신성빈혈료효우우간단급여 EPO 화자당철치료,병능유효공제당뇨병신병 MHD 환자미염증상태,개선환자생존질량。
Objective:To observe the clinical effects of combined therapy with Human erythropoietin(EPO)、iron sucrose and L - Carnitine in Maintenance hemodialysis(MHD)patients. To research the improvement of inflammation by L - Carnitine in di-abetes mellitus patients undergoing MHD. Methods:One hundred and sixty - six MHD patients were randomly divided into three groups(A、B、C). Every patients were treated by EPO,group B were treated by EPO and iron sucrose,group C were treated by EPO、iron sucrose and L - Carnitine. All the patients were treated for one year. Hemoglobin(Hb),hematokrit(HCT),Creactive protein (CRP),Triglyceride,cholesterol,total protein and albumin were examined before and after the treatment. According to the protopa-thy,the group C were divided into diabetes mellitus group(n = 18)and non diabetes mellitus group(n = 40). Observe the difference in CRP、white blood cell and neutrophile granulocyte between two groups treated with L - Carnitine. Results:The Hb level of all the three groups were higher than before. Compared with group A and group B,the HB level of group C showed much better. There was significant difference in HB level between group C and another two groups(P < 0. 05). There was significant difference in CRP be-tween group C and group A(P < 0. 05). In group C,diabetes nephropathy group showed significantly lower level of CRP(P < 0. 05). Conclusion:The combined therapy with L - Carnitine,EPO and iron sucrose was better than the treatment of EPO and iron solely. It could effectively control micro - inflammation on diabetes nephropathy and improve the quality of life.